Overview
Strateos runs a robotic cloud laboratory platform that automates life science research with on-demand, remote access to automated instruments. Researchers design, control, and monitor experiments via a web interface and pay for the specific lab services used, avoiding large in-house facilities. The platform handles steps from sample prep and cell culture to data collection and analysis, with real-time oversight, and uses 3Scan’s high-throughput tissue imaging to boost preclinical work. By offering remote, fee-for-service access that combines robotics and advanced imaging, Strateos aims to accelerate drug discovery while delivering reproducible, scalable experiments.
Work here?Claim your company
Simplify's take
What believers are saying
- A 2025 UW-Madison collaboration reported 32x more protein-sequence testing.
- That same collaboration cut experimental cycle time from weeks to seven hours.
- Zemoso's 2026 work added automated synthetic chemistry and faster customer onboarding.
What critics are saying
- Ownership remains opaque after the December 2023 Multiply Labs acquisition reports.
- LeadIQ estimates only 27 employees and $1M-$10M revenue in 2026.
- Emerald Cloud Lab, Thermo Fisher, and Benchling squeeze Strateos into a shrinking niche.
What makes Strateos unique
- LodeStar unifies experiment design, scheduling, execution, and analytics across closed-loop robotic labs.
- Strateos pairs remote cloud labs with on-site private deployments for biopharma.
- Lilly Life Sciences Studio anchors credibility with pharmaceutical automation at industrial scale.
Help us improve and share your feedback! Did you find this helpful?
